GHP Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

GHP Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$85.8K	Hold	1,500	–	–	﹤0.01%	491
2026 Q1	$84.7K	Hold	1,500	–	–	﹤0.01%	476
2025 Q4	$89.1K	Hold	1,500	–	–	﹤0.01%	463
2025 Q3	$81.2K	Hold	1,500	–	–	﹤0.01%	464
2025 Q2	$82.5K	Hold	1,500	–	–	﹤0.01%	458
2025 Q1	$106K	Hold	1,500	–	–	0.01%	418
2024 Q4	$98.6K	Hold	1,500	–	–	﹤0.01%	428
2024 Q3	$105K	Hold	1,500	–	–	﹤0.01%	430
2024 Q2	$123K	Hold	1,500	–	–	0.01%	415
2024 Q1	$131K	Hold	1,500	–	–	0.01%	415
2023 Q4	$145K	Hold	1,500	–	–	0.01%	400
2023 Q3	$130K	Hold	1,500	–	–	0.01%	406
2023 Q2	$134K	Hold	1,500	–	–	0.01%	403
2023 Q1	$146K	Hold	1,500	–	–	0.01%	397
2022 Q4	$155K	Hold	1,500	–	–	0.01%	388
2022 Q3	$127K	Hold	1,500	–	–	0.01%	394
2022 Q2	$124K	Sell	1,500 -468	-24%	-$37.3K	0.01%	398
2022 Q1	$152K	Buy	+1,968	New	+$165K	0.01%	387
2015 Q3	–	Sell	-1,500	Closed	-$217K	–	276
2015 Q2	$217K	Buy	+1,500	New	+$186K	0.05%	264

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

GHP Investment Advisors's BMRN Position: Q2 2026 in Review

GHP Investment Advisors held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 1,500 shares worth $85.8K. The position accounts for ﹤0.01% of the portfolio, ranked #491.

GHP Investment Advisors first reported a position in BMRN in Q2 2015 and has held it in 19 quarters since. The position peaked at $217K in Q2 2015. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

GHP Investment Advisors held 1,500 shares of BioMarin Pharmaceuticals worth $85.8K as of Q2 2026.
GHP Investment Advisors left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of GHP Investment Advisors's portfolio in Q2 2026, its #491 holding.
GHP Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2015 and has held it in 19 quarters since.
GHP Investment Advisors's BioMarin Pharmaceuticals position peaked at $217K in Q2 2015.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on GHP Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.